PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15622326-0 2004 CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. Tenofovir 37-46 CD4 molecule Homo sapiens 0-3 15259896-13 2004 Combination of standard doses of didanosine and tenofovir may have contributed to the CD4 cell decline observed with this QD regimen. Tenofovir 48-57 CD4 molecule Homo sapiens 86-89 15090798-0 2004 Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. Tenofovir 71-80 CD4 molecule Homo sapiens 11-14 15090798-1 2004 BACKGROUND: We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression. Tenofovir 117-126 CD4 molecule Homo sapiens 47-50 34814505-9 2021 When compared with corresponding control groups, age <35 years at ART, female, education of middle school or above, sexual transmission, no opportunistic infection, CD4 >=200 cells/mul, baseline regimen with tenofovir (TDF) and time from HIV diagnosis to ART <1 year were the related factors facilitating the higher CD4 subgroups. Tenofovir 208-217 CD4 molecule Homo sapiens 316-319 14498980-8 2003 In contrast to untreated infected control animals that showed substantial depletion of CD4+ T cells from gut-associated lymphoid tissues (GALT), tenofovir-treated animals showed sparing of GALT CD4+ T cells both during the treatment period and in the off treatment follow-up period. Tenofovir 145-154 CD4 molecule Homo sapiens 194-197 11145893-7 2001 On the contrary, the animals that received PMPA showed transient loss of CD4(+) T cells that recovered during the treatment period. Tenofovir 43-47 CD4 molecule Homo sapiens 73-76 10480261-7 1999 The compounds PCV, GCV, H2G and PMPA showed some activity in CD4+ T lymphocytes, but not in SupT1 cells. Tenofovir 32-36 CD4 molecule Homo sapiens 61-64 10400763-4 1999 Phosphonate 9-[2-(phosphomethoxypropyl]adenine (PMPA) treatment led to a moderate suppression of intestinal viral loads and repopulation of intestinal mucosa by predominantly activated memory CD4(+) T-helper cells. Tenofovir 48-52 CD4 molecule Homo sapiens 192-195 10400763-6 1999 Compared to preinfection values, the frequency of naive CD4(+) T cells increased following PMPA therapy, suggesting that new CD4(+) T cells were repopulating the intestinal mucosa. Tenofovir 91-95 CD4 molecule Homo sapiens 56-59 10400763-6 1999 Compared to preinfection values, the frequency of naive CD4(+) T cells increased following PMPA therapy, suggesting that new CD4(+) T cells were repopulating the intestinal mucosa. Tenofovir 91-95 CD4 molecule Homo sapiens 125-128 10400763-8 1999 The majority of CD4(+) T cells repopulating the intestinal mucosa following PMPA therapy were CD29(hi) and CD11ahi. Tenofovir 76-80 CD4 molecule Homo sapiens 16-19 34704355-2 2022 METHODS: In the Monitoring Early Treatment Adherence study, adherence was monitored electronically in real time among adult, treatment-naive PWH in Uganda and South Africa who initiated tenofovir disoproxil fumarate/emtricitabine/efavirenz during early-stage (CD4 > 350 cells/microL) or late-stage (CD4 < 200 cells/microL) disease. Tenofovir 186-215 CD4 molecule Homo sapiens 260-263 12396448-8 2002 The dideoxynucleoside RTI abacavir as well as the phosphonates (R)-PMPA and PMEA were more active in infected MO-DCs as compared with either CEM T cells or PHA/IL-2 activated CD4(+) T cells. Tenofovir 63-71 CD4 molecule Homo sapiens 175-178 35045162-3 2022 RESULTS: In an adjusted analysis, participants treated with tenofovir for at least 4 years had shorter TL in CD8+ T cells (P = 0.04) and lower telomerase activity in CD4+ (P = 0.012) and CD8+ T cells (P = 0.023). Tenofovir 60-69 CD4 molecule Homo sapiens 166-169 31143861-8 2019 The mean increase in CD4 count (57.16%) after 6 months was statistically significant (P < 0.05) with tenofovir + lamivudine + atazanavir/ritonavir regimen in forty patients. Tenofovir 104-113 CD4 molecule Homo sapiens 21-24 31597561-11 2019 Patients with normal BMI compared to underweight, (HR: 0.79, CI 0.69-0.91), with CD4 counts 200-350 cells/microL compared to < 200 cells/microL (HR: 0.81- CI 0.71-0.93), and started on zidovudine (HR: 0.51 CI 0.44-0.59) and tenofovir (HR: 0.16, CI 0.14-0.22) compared to stavudine were less likely to have ART modification due to toxicity. Tenofovir 224-233 CD4 molecule Homo sapiens 81-84 30755713-1 2019 Tenofovir (TFV) treatment of female reproductive tract (FRT) cells results in differential accumulation of intracellular Tenofovir diphosphate (TFV-DP) in different cell types, with greater concentrations in epithelial cells (100-fold) and fibroblasts (10-fold) than in CD4+ T cells. Tenofovir 0-9 CD4 molecule Homo sapiens 270-273 30755713-1 2019 Tenofovir (TFV) treatment of female reproductive tract (FRT) cells results in differential accumulation of intracellular Tenofovir diphosphate (TFV-DP) in different cell types, with greater concentrations in epithelial cells (100-fold) and fibroblasts (10-fold) than in CD4+ T cells. Tenofovir 11-14 CD4 molecule Homo sapiens 270-273 26906233-4 2016 He was receiving treatment with efavirenz, emtricitabine and tenofovir, his CD4 count was 580/mm3 and HIV viral load was undetectable. Tenofovir 61-70 CD4 molecule Homo sapiens 76-79 29850480-0 2018 Tenofovir-Based Highly Active Antiretroviral Therapy Is Associated with Superior CD4 T Cells Repopulation Compared to Zidovudine-Based HAART in HIV 1 Infected Adults. Tenofovir 0-9 CD4 molecule Homo sapiens 81-84 29850480-8 2018 After five months of the HAART, the tenofovir cohort recorded higher CD4 T cell count change from baseline compared to the zidovudine cohort (p < 0.0001). Tenofovir 36-45 CD4 molecule Homo sapiens 69-72 29707599-8 2018 Conclusions: Our study found a low prevalence of renal impairment among PLWHIV despite high usage of tenofovir and its association with age, hypertension, low CD4 count, and advanced WHO stage. Tenofovir 101-110 CD4 molecule Homo sapiens 159-162 27231099-7 2016 Failure in the tenofovir-only group was associated with lower CD4 values and advanced WHO stage. Tenofovir 15-24 CD4 molecule Homo sapiens 62-65 29424790-10 2018 Vaginal tissue TFV concentrations were significantly positively correlated with vaginal epithelial thickness, whereas vaginal tissue TFV-DP concentrations were positively correlated with density of vaginal CD4 and CD8 immune cells. Tenofovir 133-136 CD4 molecule Homo sapiens 206-209 27646953-5 2016 CASES PRESENTATION: A first case was a 33 years-old female newly diagnosed HIV patient with CD4 count of 4 cells/muL (0 %), normal complete blood count, liver and renal function tests was started on co-formulated tenofovir/emtricitabine/efavirenz and prophylactic cotrimoxazole. Tenofovir 213-222 CD4 molecule Homo sapiens 92-95 26598082-9 2015 After adjustment for variables with p<0.2 in the univariate analysis using a Poisson regression model, tenofovir-containing regimens and a CD4 lymphocyte count below 200 cells/mm3 were significantly associated with pathological proteinuria. Tenofovir 106-115 CD4 molecule Homo sapiens 142-145 27032851-10 2016 Clinicians were more likely to stop tenofovir in patients with lower CrCl and CD4 count. Tenofovir 36-45 CD4 molecule Homo sapiens 78-81 25350130-8 2014 The EC50 for CD4+MMC was within the single topical treatment range, providing evidence that a 1% topical, vaginally-formulated TFV gel provided in-vivo doses predicted to provide for 50% efficacy in the ex vivo assay. Tenofovir 127-130 CD4 molecule Homo sapiens 13-16 26157126-12 2015 HIV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in almost half the mice by preexposure prophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the tenofovir microbicide gel utilized in CAPRISA-004, VOICE, and FACTS-001 clinical trials. Tenofovir 184-213 CD4 molecule Homo sapiens 19-23 26157126-12 2015 HIV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in almost half the mice by preexposure prophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the tenofovir microbicide gel utilized in CAPRISA-004, VOICE, and FACTS-001 clinical trials. Tenofovir 184-193 CD4 molecule Homo sapiens 19-23 25247433-9 2015 Overall mean CD4 counts were 463 and 514 cells per microliter in women assigned to tenofovir and placebo (P = 0.290). Tenofovir 83-92 CD4 molecule Homo sapiens 13-16 25350130-9 2014 The 7-daily topical TFV gel treatment provided TFVdp concentrations that reached EC90 biopsy efficacy for CD4-MMC, CD4+MMC and TotalMMC compartments. Tenofovir 20-23 CD4 molecule Homo sapiens 106-109 25350130-9 2014 The 7-daily topical TFV gel treatment provided TFVdp concentrations that reached EC90 biopsy efficacy for CD4-MMC, CD4+MMC and TotalMMC compartments. Tenofovir 20-23 CD4 molecule Homo sapiens 115-118 25350130-10 2014 CONCLUSION: The TFVdp MMC compartment (CD4+, CD4- and Total) provided the best surrogate for biopsy infectibility and the 7-daily topical TFV gel treatment provided the strongest PK profile for HIV suppression. Tenofovir 16-19 CD4 molecule Homo sapiens 39-42 23892239-6 2013 The estimated CD4 recovery on cART was similar between HIV monoinfection and HIV-HBV coinfection groups and between lamivudine- and tenofovir-treated participants. Tenofovir 132-141 CD4 molecule Homo sapiens 14-17 24296645-8 2014 Patients on tenofovir were more likely to have switched to second-line ART in recent years, spent more time on first-line ART (33 versus 24 months) and had lower CD4(+) T-cell counts (172 versus 341 cells/mul) at initiation of second-line ART. Tenofovir 12-21 CD4 molecule Homo sapiens 162-165 19737231-8 2009 The proportion of CD4(+)CD45RA(+) T cells and of functionally inhibited killer immunoglobulin-like receptor T cell receptor alphabeta(+) cells, the proliferation to recall antigens as well as NK cell phenotype and function as determined by interferon-gamma production in patients treated with tenofovir-didanosine were comparable to those treated with a different regimen. Tenofovir 293-302 CD4 molecule Homo sapiens 18-21 23475910-6 2013 Within two months, concomitantly with initiation of raltegravir, etravirine and emcitricabine/tenofovir, the patient recovered, gained weight, resumed walking and his CD4 counts rose from 270 to 450 cells/mm(3). Tenofovir 94-103 CD4 molecule Homo sapiens 167-170 23079810-9 2013 In multivariate analysis tenofovir-based regimens were less likely to have at least three nucleoside reverse transcriptase inhibitor (NRTI) mutations after adjusting for subtype, previous ART, CD4, and HIV viral load [P < 0.001, odds ratio (OR) 0.04]. Tenofovir 25-34 CD4 molecule Homo sapiens 193-196 22193343-9 2012 CONCLUSIONS: We found that both viral load and CD4+CD25+FOXP3+ nTreg percentages decreased significantly in patients with chronic hepatitis B virus infection during 1 year course of tenofovir treatment. Tenofovir 182-191 CD4 molecule Homo sapiens 47-50 21628669-3 2011 METHODS: TFV accumulation was assessed in parental and ABCC10-transfected HEK293 cells (HEK293-ABCC10), CD4(+) cells and monocyte-derived macrophages (MDMs). Tenofovir 9-12 CD4 molecule Homo sapiens 104-107 20515419-9 2010 Among tenofovir users, factors associated with a reduction in GFR included female gender (p < 0.001), African American ethnicity (p = 0.003), and lower CD4 nadir (p = 0.002). Tenofovir 6-15 CD4 molecule Homo sapiens 155-158 20515419-12 2010 Factors associated with renal loss among tenofovir users included female gender, African American ethnicity, and CD4 nadir <200 cells/mm(3). Tenofovir 41-50 CD4 molecule Homo sapiens 113-116 20452889-4 2010 Introduction of an integrase-inhibitor regimen based on raltegravir, tenofovir, and emtricitabine allowed a prompt achievement of undetectable viral load and a substantial rise of CD4 count to high levels, with no subsequent episodes of hepatic toxicity, and no other side effects. Tenofovir 69-78 CD4 molecule Homo sapiens 180-183 20233398-6 2010 When emtricitabine (FTC) and tenofovir (PMPA) were added to treatment, undetectable viral load was reached in two weeks, and a parallel increase in CD4 counts was observed. Tenofovir 29-38 CD4 molecule Homo sapiens 148-151 20233398-6 2010 When emtricitabine (FTC) and tenofovir (PMPA) were added to treatment, undetectable viral load was reached in two weeks, and a parallel increase in CD4 counts was observed. Tenofovir 40-44 CD4 molecule Homo sapiens 148-151 17177308-9 2007 After 4 weeks of treatment with tenofovir 600 mg, the median decrease in the viral load was -0.61 log(10) (range -0.05; -0.88) and the median gain of CD4 was +109/mm(3). Tenofovir 32-41 CD4 molecule Homo sapiens 150-153 19432547-3 2009 We evaluated 4 patients with a history of CD4(+) T cell decline despite successfully suppressive ART, from a median of 719 cells/mm(3) (range, 360-1141 cells/mm(3)) to 227 cells/mm(3) (range, 174-311 cells/mm(3)) over a period of 18-24 months; 3 of the patients were receiving tenofovir and didanosine, which may have contributed to this decrease. Tenofovir 277-286 CD4 molecule Homo sapiens 42-45 18770899-0 2008 CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load. Tenofovir 32-41 CD4 molecule Homo sapiens 0-3 17341536-6 2007 DISCUSSION: Paradoxical declines in CD4+ cell counts have been reported in HIV-infected patients virally suppressed on tenofovir/didanosine regimens, presumably via inhibition of purine nucleoside phosphorylase (PNP) by tenofovir and enhancement of didanosine toxicity. Tenofovir 119-128 CD4 molecule Homo sapiens 36-39 17341536-6 2007 DISCUSSION: Paradoxical declines in CD4+ cell counts have been reported in HIV-infected patients virally suppressed on tenofovir/didanosine regimens, presumably via inhibition of purine nucleoside phosphorylase (PNP) by tenofovir and enhancement of didanosine toxicity. Tenofovir 220-229 CD4 molecule Homo sapiens 36-39 19398921-9 2009 CD4 counts and plasma lipids showed higher increments in the abacavir/lamivudine group than in the tenofovir/emtricitabine group. Tenofovir 99-108 CD4 molecule Homo sapiens 0-3 17434879-1 2007 BACKGROUND: Tenofovir with full-dose didanosine has been associated with paradoxical CD4 + T cell decrease despite virological suppression. Tenofovir 12-21 CD4 molecule Homo sapiens 85-88 17926643-8 2007 Patients on tenofovir showed significantly lower CD4+ T-cell increases compared with stavudine. Tenofovir 12-21 CD4 molecule Homo sapiens 49-52 17926643-9 2007 CONCLUSIONS: In our observational study, long-term CD4+ T-cell increase in drug-naive patients with suppressed VL was higher in regimens without tenofovir. Tenofovir 145-154 CD4 molecule Homo sapiens 51-54 16717052-0 2006 Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. Tenofovir 84-93 CD4 molecule Homo sapiens 23-26 17127826-3 2006 Patients with low CD4 cell count, low body weight and with concomitant diseases such as arterial hypertension and diabetes or co-infections with HCV, HBV or Treponema pallidum seem at higher risk of tenofovir-related nephrotoxicity. Tenofovir 199-208 CD4 molecule Homo sapiens 18-21 16956530-9 2006 In patients treated with TDF + 3TC, CD4 count increased by 160 cel/microl (95% CI, 53-266) more than in patients treated with TDF + ddI; and in patients receiving ddI + 3TC, CD4+ count increased by 138 cel/microl (95% CI, 25-266) more than in patients receiving TDF + ddI. Tenofovir 25-28 CD4 molecule Homo sapiens 36-39 16956530-9 2006 In patients treated with TDF + 3TC, CD4 count increased by 160 cel/microl (95% CI, 53-266) more than in patients treated with TDF + ddI; and in patients receiving ddI + 3TC, CD4+ count increased by 138 cel/microl (95% CI, 25-266) more than in patients receiving TDF + ddI. Tenofovir 25-28 CD4 molecule Homo sapiens 174-177 16691065-6 2006 Comparing two drug nucleoside backbones, there was a lower annual change in CD4 cell count for zidovudine/lamivudine (n = 13038; -15.4/microl; P = 0.012) and for those on tenofovir (n = 1809; -27.3/microl; P = 0.029) compared to lamivudine/stavudine (n = 7339). Tenofovir 171-180 CD4 molecule Homo sapiens 76-79 16691065-8 2006 CONCLUSIONS: A nucleoside backbone of zidovudine/lamivudine or any tenofovir-based backbone was associated with significantly poorer increases in CD4 cell count compared to a nucleoside backbone of stavudine/lamivudine, as was an abacavir-based triple nucleoside regimen compared to a boosted protease inhibitor regimen. Tenofovir 67-76 CD4 molecule Homo sapiens 146-149 16107993-1 2005 The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Tenofovir 44-53 CD4 molecule Homo sapiens 95-98 16531427-0 2006 Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. Tenofovir 72-81 CD4 molecule Homo sapiens 11-14 16531427-4 2006 As an example, the combination of didanosine and tenofovir has recently been associated with a paradoxical depletion of CD4+ T cells in the face of complete viral suppression. Tenofovir 49-58 CD4 molecule Homo sapiens 120-123 16184059-0 2005 Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens. Tenofovir 139-148 CD4 molecule Homo sapiens 104-107 15958845-0 2005 Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen. Tenofovir 60-69 CD4 molecule Homo sapiens 17-20 15958845-1 2005 In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed. Tenofovir 57-66 CD4 molecule Homo sapiens 31-34 15802975-0 2005 Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. Tenofovir 96-105 CD4 molecule Homo sapiens 12-15